Mizuho raised the firm’s price target on Crispr Therapeutics to $99 from $82 and keeps a Buy rating on the shares. The analyst continues to believe Crispr could have several catalysts in 2024 and beyond.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- Crispr Therapeutics call volume above normal and directionally bullish
- Crispr Therapeutics price target raised to $66 from $57 at RBC Capital
- Crispr Therapeutics price target raised to $70 from $55 at Wells Fargo
- Crispr Therapeutics price target raised to $80 from $61 at Barclays
- Crispr Therapeutics price target raised to $112 from $110 at Chardan
